Markel International appoints Collin Sim as first Casualty Underwriter in Singapore
SINGAPORE, June 25, 2025 /CNW/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE:MKL), today announced the appointment of Collin Sim as Casualty Underwriter, marking the establishment of the company's first dedicated casualty underwriting position in Singapore.
In her new role, Sim will be responsible for developing Markel's Casualty presence in Southeast Asia and the broader Asian market. She will focus on building and maintaining strategic relationships with brokers and clients while managing a portfolio of risks in accordance with Markel's underwriting principles. Her appointment supports the company's strategic expansion of casualty underwriting capabilities across the Asia Pacific region.
Sim brings over two decades of casualty underwriting expertise across Asia to Markel. She most recently served as Assistant Vice President of General Casualty at Allied World, where she was responsible for managing general casualty direct and facultative business across Southeast Asian markets. Prior to that, she spent 17 years at Gen Re, where she played an instrumental role in developing casualty facultative books across multiple Asian markets, including Singapore, Malaysia, Brunei, and China.
Wanshi Lin, Head of Singapore, said: "We are delighted to welcome Collin to Markel. Her extensive experience and deep understanding of the Asian casualty market will be invaluable as we continue to expand our presence in the region. This strategic appointment demonstrates our commitment to building strong underwriting capabilities and delivering exceptional service to our clients and partners across Asia Pacific."
Christian Stobbs, Managing Director - Asia Pacific, commented: "Collin's appointment represents a significant milestone in our regional growth strategy. Her proven track record in developing profitable casualty portfolios and her deep relationships across the Asian insurance market make her the ideal candidate to establish and grow our casualty practice in Singapore."
About Markel InsuranceWe are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/markel-international-appoints-collin-sim-as-first-casualty-underwriter-in-singapore-302491457.html
SOURCE Markel
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/25/c5858.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
an hour ago
- News24
Avoid regret: Insurance tips for making smarter decisions
Insurance adds value to both life and items we own, offering stability, security, and peace of mind. It plays a critical role in helping us manage life's uncertainties that have financial implications. Santam's 2025 insurance barometer report, surveying nearly 900 South African customers, businesses and brokers, highlights the emerging risks we face today. It makes a case for the importance of informed, forward-thinking insurance decisions. The risks identified in South Africa The report notes how South African households are feeling impacted by the persistently high inflation and interest rates, with 84 percent of consumer survey respondents saying they have had to make adjustments to cope with the increased cost of living. Atang Matebesi, CEO of Santam Client Solutions, notes how the changes in the local and international risk landscape mean the local short-term insurance industry must continue to adapt at a rapid pace. Atang says, 'Weather volatility, infrastructure concerns and socio-economic challenges have created a tough environment for local insurers.' READ MORE | 6 ways to master financial resilience through tough economic times Beyond the cost of living, the report highlights other concerns, which include: Crime - '16 percent more consumer respondents citing it as a top three risk for their households now, compared with 2023'. Climate change - '78 percent of consumers citing they are in some way concerned about the threat of extreme weather events'. Cost of living - 47 percent cite economic challenges. With the changing role of insurance brokers, the report highlights how insurers must provide meaningful risk management tools. Beyond this, there's the growing question of how to make more informed insurance choices. Where does it start and where does it end? Types of insurance Investopedia, a U.S.-based financial publication, notes these four types of crucial insurance policies you need: Life insurance; Health insurance; Long-term disability coverage; and Car-insurance. READ MORE | Nicolette Mashile on financial literacy - 'It should be a basic human right' Tips on picking the right insurance policy for you South Africa-based MiSure Insurance Brokers suggests you consider the following:
Yahoo
an hour ago
- Yahoo
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Forbes
an hour ago
- Forbes
Billionaire Charoen's Frasers Property, Partners Offer Top Bid Of $387 Million For Prime Singapore Plot
Singapore's residential properties are among the most expensive in the world. A consortium that includes Frasers Property—controlled by Thai billionaire Charoen Sirivadhanabhakdi and his family—submitted the highest bid of S$491.5 million ($387 million) for a residential plot in Singapore's upscale Bukit Timah neighborhood. Frasers Property and its partners Japan's Sekisui House and CSC Land, a unit of Beijing-based China State Construction Engineering Corp, outbid eight other groups for the hotly contested plot on the site of the former Singapore Turf City horse racing track until 1999 when it moved to the western Singapore town of Kranji. The government is closing the Kranji race track for good in 2027 and developing a housing estate on the property. Other bidders for the 99-year leasehold site on Dunearn Road include City Developments, controlled by real estate tycoon Kwek Leng Beng and his family, as well as billionaire Wee family's UOL Group, which partnered with unit Singapore Land and privately owned Kheng Leong Co. About 380 residential condominium units can be built on the 13,492 square meter site, according to the Urban Redevelopment Authority. The site is located within a coveted residential enclave near the Sixth Avenue MRT station, Leonard Tay, head of research at property consultancy Knight Frank in Singapore, said in an emailed statement. 'With limited new launches in the area in recent months, pent-up domestic demand particularly from owner-occupiers familiar with Bukit Timah's character and education belt is expected to support interest at [the project's]The project may sell for as much as S$3,200 per square foot, above the effective top bid of S$1,410 per square foot per plot ratio, Tay added. Frasers Property has been stepping up residential developments to tap into resilient demand for luxury homes in the city-state. Last November, it partnered with Sekisui House to redevelop a serviced apartment along the Singapore River near the Raffles Place central business district into a mixed use residential and retail complex. Charoen, 81, is Thailand's third-richest person with a net worth of $10.6 billion based on real-time Forbes data. The self-made billionaire took control of Frasers Property—which owns residential, offices, shopping malls, logistics properties and hotels across Australia, China, Europe and Southeast Asia—following his takeover of Fraser & Neave in 2013. Charoen also owns Chang beer maker Thai Beverages and Bangkok-based developer Asset World Corp.
